NCT01442792View on ClinicalTrials.gov

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 12, 2011

Primary Completion Date

January 29, 2013

Study Completion Date

March 4, 2013

Conditions
Cardiovascular DiseaseCoronary Artery Disease
Interventions
DRUG

UFH

Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

10 mg single dose Rivaroxaban (per os)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg single dose Rivaroxaban (per os)

DRUG

Rivaroxaban (Xarelto, BAY59-7939) and UFH

10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)

Trial Locations (7)

3500

Hasselt

4000

Liège

8800

Roeselare

1091 AC

Amsterdam

1105 AZ

Amsterdam

5623 EJ

Eindhoven

8011 JW

Zwolle

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY